great
pleasur
salut
isar
member
friend
new
issu
isar
news
th
icar
atlanta
success
mani
way
receiv
excel
comment
congratul
excel
qualiti
invit
speaker
mani
oral
poster
present
icar
retain
flavor
person
provid
interdisciplinari
forum
investig
involv
basic
translat
clinic
research
worldwid
meet
review
recent
develop
area
antivir
research
drug
vaccin
develop
mention
new
format
icar
report
publish
antivir
research
highlight
review
oral
present
addit
satellit
activ
women
scienc
roundtabl
career
develop
panel
new
member
first
time
attende
luncheon
happi
hour
provid
opportun
discuss
issu
relev
take
opportun
thank
cochair
program
committe
justin
juland
mark
prichard
committe
chair
member
unselfish
commit
organ
confer
th
icar
meant
challeng
societi
mani
differ
compet
confer
meet
attend
long
econom
crisi
scientif
research
escap
isar
gone
great
financi
effort
continu
support
particip
student
postdoc
young
investig
happi
learn
th
icar
break
trend
meet
becom
financi
sound
indebt
corpor
sponsor
friend
societi
isar
member
contribut
encourag
financi
support
continu
organ
best
antivir
meet
possibl
excel
scienc
support
young
investig
continu
drive
effort
begin
organ
st
icar
held
porto
portug
confer
begin
monday
june
conclud
porto
select
easi
access
flight
european
citi
major
us
hub
also
dazzl
warmth
beauti
porto
citi
full
tradit
cultur
modern
exit
mani
year
organ
meet
hotel
venu
st
icar
held
congress
centr
http
wwwccalfandegaportocomen
hope
free
icar
particip
constraint
stay
venu
hotel
allow
everyon
choos
accommod
suit
need
popular
tourist
locat
porto
mani
type
accommod
offer
luxuri
hotel
small
comfort
hostel
isar
block
limit
number
room
differ
hotel
encourag
everyon
make
time
reserv
stay
porto
continu
support
particip
student
postdoc
young
investig
travel
support
sole
base
merit
excel
abstract
submit
present
encourag
wish
appli
submit
best
scienc
qualiti
prevail
criteria
receiv
financi
support
keep
eye
instruct
submit
abstract
isaricar
websit
http
wwwisaricarcom
kindli
remind
member
call
nomin
isar
award
open
encourag
nomin
deserv
colleagu
isar
chu
famili
foundat
scholarship
women
scientist
also
open
applic
award
given
advanc
career
women
potenti
signific
contribut
field
antivir
research
inform
submit
nomin
post
websit
request
inform
societi
email
address
shown
earli
stage
organ
st
icar
call
interest
particip
let
us
know
idea
comment
suggest
particular
interest
topic
highlight
pleas
feel
free
contact
us
let
us
know
info
isaricarcom
isar
held
annual
busi
meet
atlanta
hilton
th
icar
wednesday
may
brian
gowen
treasur
present
brief
summari
societi
financ
net
asset
end
fiscal
year
sever
bank
account
two
invest
account
cd
matur
august
tabl
net
asset
total
end
fiscal
year
larg
due
deficit
th
icar
held
la
jolla
ca
see
isar
news
vol
although
downward
trend
societi
hold
figur
project
review
revenu
expens
icar
favor
know
final
number
late
juli
august
revenu
support
receiv
meet
expens
paid
inform
provid
upcom
issu
isar
news
also
present
busi
meet
yearend
financi
statement
reflect
isar
revenu
sourc
expens
tabl
largest
sourc
revenu
support
receiv
gener
sponsor
confer
registr
fee
major
annual
expens
annual
icar
graciela
andrei
secretari
provid
report
isar
membership
attend
th
icar
atlanta
figur
twentyon
countri
repres
societi
total
member
may
usa
total
attende
may
differ
countri
regist
th
icar
year
societi
receiv
applic
travel
grant
award
restrict
budget
avail
grant
applic
could
e
fund
base
scientif
review
submit
abstract
rank
establish
base
score
provid
four
independ
review
societi
award
travel
merit
grant
north
america
europ
asia
australia
receiv
award
respect
help
member
defray
cost
attend
confer
societi
also
award
travel
merit
assist
award
particip
come
lowmiddleincom
countri
support
attend
meet
recipi
award
besid
stipend
registr
fee
waiv
shown
figur
societi
invest
total
travel
award
year
highlight
consider
fund
made
avail
societi
past
year
increas
attend
young
investig
meet
year
icar
poster
competit
atlanta
alway
fierc
highli
competit
intern
team
judg
includ
graciela
andrei
john
bigger
andrea
brancal
jinhong
chang
cyril
dousson
joana
rochapereira
brian
gentri
zlatko
janeba
brent
korba
chri
meier
jennif
moffat
roger
ptak
lui
schang
enzo
tramontano
chair
poster
award
committe
kathi
seleyradtk
fiftyfour
poster
regist
judg
three
categori
undergraduategradu
student
postdoctor
research
young
investig
categori
mani
excel
poster
run
poster
prize
chanc
give
shotgun
talk
wednesday
open
session
cochair
kathi
seleyradtk
graduat
student
theres
ku
poster
committe
would
like
thank
present
excel
research
present
look
forward
judg
next
year
entri
porto
rhonda
cardin
th
annual
women
scienc
roundtabl
open
event
th
icar
atlanta
georgia
featur
panel
discuss
particip
engag
interact
discuss
four
lead
women
scientist
respect
field
includ
priscilla
yang
harvard
medic
school
inger
damon
cdc
juli
dyall
niaid
nih
tunnel
consult
compani
introduc
rhonda
cardin
louisiana
state
univers
panel
member
share
person
profession
experi
well
opportun
challeng
encount
scientif
career
brought
forth
mani
vari
viewpoint
provid
food
thought
particip
provok
insight
question
lead
enthusiast
discuss
appreci
panel
member
particip
attend
event
look
forward
see
everyon
th
annual
women
scienc
roundtabl
porto
atlanta
wi
committe
pleas
present
priscilla
yang
harvard
univers
first
wi
sponsor
speaker
recognit
major
contribut
antivir
research
leadership
mentor
young
women
yang
present
research
small
molecul
inhibitor
viral
entri
pharmacolog
mimicri
humor
immun
respons
viral
infect
antivir
immun
symposium
hope
first
mani
invit
speaker
highlight
research
accomplish
women
scienc
thank
gener
donat
chu
famili
pleas
announc
chu
famili
foundat
tcff
award
women
scientist
tcff
award
support
profession
develop
women
potenti
make
signific
contribut
field
antivir
research
provid
fund
attend
confer
visit
anoth
laboratori
take
cours
acquir
special
train
award
given
annual
icar
meet
award
dengu
fever
diseas
caus
four
serotyp
dengu
viru
denv
mostli
transmit
urban
dwell
aed
aegypti
mosquito
close
global
human
popul
live
dengu
endem
area
risk
contract
diseas
poorli
control
urban
develop
vector
spread
thought
associ
global
warm
possibl
contributor
expans
dengu
gubler
estim
around
million
symptomat
dengu
case
occur
total
nearli
million
infect
bhatt
et
al
diseas
manifest
rang
asymptomat
mild
undifferenti
dengu
fever
df
symptomat
case
progress
seriou
lifethreaten
complic
result
vascular
leakag
hemorrhag
organ
dysfunct
simmon
et
al
low
et
al
secondari
dengu
infect
often
consist
associ
sever
dengu
diseas
part
antibodi
depend
enhanc
ade
phenomenon
halstead
vaccin
measur
counter
spread
dengu
agenda
nation
health
author
mani
decad
still
remain
high
prioriti
world
health
organ
russel
recker
et
al
confer
dengu
held
singapor
predict
would
take
year
develop
tetraval
dengu
vaccin
russel
howev
unexpect
challeng
develop
vaccin
took
nearli
four
decad
first
dengu
vaccin
develop
sanofi
pasteur
licens
sever
countri
sinc
decemb
attenu
live
recombin
vaccin
gener
splice
prm
e
gene
denv
yellow
fever
viru
yfv
vaccin
strain
genom
replac
yfv
prm
e
gene
yield
chimer
yellow
fever
dengu
vaccin
cydtdv
dengvaxia
administ
dose
month
schedul
clinic
studi
found
overal
efficaci
serotypespecif
efficaci
denv
respect
vaccin
recommend
use
individu
year
age
live
dengu
endem
region
diseas
burden
high
achiev
sanofi
pasteur
commend
mark
import
mileston
dengu
control
exemplari
partnership
larg
number
public
privat
institut
around
world
valuabl
lesson
learn
dengu
vaccin
candid
current
explor
improv
efficaci
extend
age
coverag
also
simplifi
vaccin
schedul
order
achiev
wider
vaccin
accept
uptak
apart
vaccin
vector
control
strategi
use
wolbachia
bacteria
reduc
capac
aed
aegypti
mosquito
transmit
dengu
activ
explor
mani
countri
larg
support
bill
melinda
gate
foundat
http
wwweliminatedenguecom
dengu
antivir
research
develop
potenti
intervent
approach
receiv
boost
novarti
pharma
form
publicpriv
partnership
singapor
econom
develop
board
establish
novarti
institut
tropic
diseas
nitd
expect
safe
oral
avail
drug
use
year
old
e
activ
four
denv
serotyp
capabl
reduc
dengu
symptom
incid
sever
dengu
could
achiev
year
period
keller
et
al
although
drug
eventu
far
effort
nitd
led
mani
promis
lead
target
protein
contain
enzymat
activ
necessari
viral
rna
replic
lead
review
lim
colleagu
lim
et
al
meantim
major
stride
understand
structur
function
viral
target
well
dengu
pathogenesi
gener
made
stateoftheart
research
use
structur
studi
cryoelectron
microscopi
revers
genet
rnai
screen
crispr
screen
whole
genom
deep
sequenc
anim
model
studi
contribut
data
aris
new
approach
hold
promis
develop
directlyact
antivir
daa
host
factor
target
viral
process
viral
entryfus
ii
translationpolyprotein
process
iii
rna
replic
iv
packagingviru
matur
howev
order
make
impact
one
viabl
intervent
approach
dengu
control
alongsid
vaccin
vector
control
measur
import
efficaci
dengu
antivir
drug
reach
clinic
first
half
next
decad
signific
challeng
consid
bottleneck
drug
develop
late
preclin
clinic
develop
phase
one
way
mitig
format
research
consortia
partnership
involv
wellcom
trustku
leuvenjanssen
dengu
drug
develop
http
wwwjanssencompartnershipsdengu
develop
pipelin
candid
drug
rapidli
evalu
develop
potent
dengu
antivir
similar
partnership
nation
institut
health
usa
european
union
nation
agenc
part
world
also
help
link
larg
bodi
work
academ
laboratori
small
biotechnolog
compani
ensur
potenti
candid
drug
success
enter
clinic
test
task
manag
intellectu
properti
expect
partner
within
consortia
streamlin
work
type
partnership
result
fruit
outcom
diseas
dengu
emerg
viral
diseas
new
opportun
develop
panflavivir
drug
arisen
especi
sinc
close
relat
zika
viru
zikv
outbreak
fauci
moren
infect
zikv
result
congenit
deform
newborn
babi
mother
infect
pregnanc
well
syndrom
otherwis
healthi
adult
brought
intens
intern
focu
emerg
threat
call
urgent
develop
antivir
drug
flavivirus
carri
singlestrand
posit
sens
rna
genom
nucleotid
encod
amino
acid
residu
polyprotein
precursor
cleav
three
structur
protein
capsid
premembranemembran
envelop
seven
nonstructur
ns
protein
crystal
structur
enzym
target
zikv
reveal
extens
structur
similar
denv
flavivirus
form
excel
start
point
develop
novel
daa
case
zikv
proteas
shown
binari
express
construct
constrain
artifici
linker
modifi
nativ
linker
result
high
resolut
crystal
structur
wrap
around
molecul
close
conform
leav
substrat
bind
site
empti
bind
small
molecul
crystal
amen
fragment
base
screen
structuredirect
antivir
develop
zhang
et
al
case
structur
also
show
high
similar
nucleosid
inhibitor
nitd
wide
use
control
drug
screen
effort
differ
compound
librari
barrow
et
al
xu
et
al
opportun
nonnucleosid
inhibitor
also
exist
sinc
structur
similar
reveal
conserv
pocket
near
region
critic
denovo
initi
viral
rna
replic
target
import
lesson
learn
conduct
dengu
antivir
clinic
trial
use
repurpos
drug
review
recent
low
et
al
strategi
wide
systemat
appli
discov
novel
individu
combin
compound
potenti
panflavivir
drug
given
acut
natur
dengu
narrow
window
opportun
antivir
treatment
like
number
patient
recruit
evalu
efficaci
drug
may
limit
earli
phase
clinic
trial
addit
high
cost
larg
trial
long
studi
durat
may
limit
number
compound
enter
phase
iiiii
trial
detriment
effect
whole
process
drug
discoveri
develop
recent
year
limit
larg
random
clinic
trial
wide
acknowledg
sever
impair
medic
advanc
adapt
trial
part
address
clinic
endpoint
requir
larg
sampl
size
use
dengu
trial
altern
robust
biomark
fluorodeoxyglucos
fdg
recent
examin
preclin
anim
model
goal
drug
efficaci
could
directli
correl
reduct
fdg
signal
reflect
virusinduc
inflamm
use
positron
emiss
tomographi
pet
imag
chacko
et
al
observ
preclin
studi
translat
human
case
conceiv
smaller
phase
ii
trial
rapidli
conduct
triag
pipelin
drug
variou
consortia
would
valuabl
robust
biomark
evalu
similar
goal
summari
success
develop
antivir
hepat
c
viru
serv
exampl
possibl
develop
potent
denguepanflavivir
antivir
bar
may
view
littl
higher
case
dengu
avail
fund
probabl
fraction
avail
hcv
antivir
develop
howev
task
insurmount
partnership
consortia
led
success
develop
dengvaxia
recapitul
dengu
antivir
develop
deliv
drug
deploy
clinic
use
rega
institut
medic
research
ku
leuven
univers
leuven
leuven
belgium
lievenaesen
kuleuvenb
year
antivir
research
celebr
th
anniversari
g
elion
first
public
acyclovir
well
th
anniversari
zidovudin
first
drug
becom
approv
hiv
therapi
event
repres
landmark
clinic
manag
viru
infect
class
nucleo
ide
inhibitor
hiv
rt
ripen
becom
cornerston
hiv
treatment
drug
prove
equal
valuabl
hepat
b
sinc
approv
sofosbuvir
hepat
c
anoth
viral
diseas
nucleo
ide
inhibitor
appear
hard
compet
sofosbuvir
first
nucleotid
drug
act
chain
termin
viral
rnadepend
rna
polymeras
newer
analogu
rsv
inhibitor
activ
ebola
plu
rna
virus
clinic
pipelin
hope
address
import
unmet
medic
need
look
molecul
gain
success
clinic
approv
structur
variat
nucleo
ide
theme
still
quit
limit
contrast
larg
chemic
varieti
among
experiment
nucleo
ide
synthes
proven
antivir
activ
preclin
earli
clinic
studi
exampl
rather
exot
sugar
replac
dioxolan
sixmemb
ring
conform
lock
ring
likewis
quit
drastic
variat
base
part
accept
exemplifi
two
carboxamid
compound
ribavirin
favipiravir
herpesviru
inhibitor
brivudin
valnivudin
evid
viral
polymeras
highli
promiscu
abl
recogn
nucleosidetriphosph
analogu
unusu
unnatur
structur
hiv
rt
viral
rnadepend
rna
polymeras
lack
proofread
activ
surpris
howev
even
herpesviru
polymeras
possess
exonucleas
activ
seem
easili
fool
fact
defin
antivir
spectrum
often
assign
antivir
nucleo
tide
simplist
instanc
tenofovir
inhibit
hsv
cidofovirdiphosph
inhibit
hiv
rt
dideoxynucleosid
inhibitor
hiv
also
activ
adenoviru
penciclovir
inhibit
hepat
b
viru
recent
exampl
broad
antirna
viru
agent
structur
divers
antivir
nucleo
ide
drug
still
quit
limit
import
restrict
lie
within
host
cell
possess
varieti
purin
pyrimidineconvert
kinas
act
tightli
control
pathway
connect
nuclear
mitochondri
dna
rna
synthesi
except
nucleosid
diphosphatas
ndp
kinas
kinas
gener
display
narrow
substrat
specif
antivir
kinas
depend
repres
daunt
barrier
sinc
unnatur
nucleo
ide
mere
bind
kinas
importantli
act
effici
substrat
smoothli
phosphoryl
bypass
first
often
ratelimit
first
phosphoryl
step
monophosph
format
like
tenofovir
sofosbuvir
design
recent
success
diand
triphosph
prodrug
concept
develop
meier
colleagu
creat
possibl
design
antivir
nucleotid
less
obviou
chemic
structur
base
ribos
part
given
lack
proofread
activ
vast
major
rna
virus
coronavirus
except
diand
triphosph
prodrug
could
one
way
achiev
broad
antirna
viru
agent
desper
need
tackl
emerg
potenti
pandem
virus
anoth
issu
worthi
thought
whether
obligatenonoblig
chain
termin
reli
incorpor
antivir
nucleotid
realli
absolut
requir
wherea
oblig
chain
termin
lack
hydroxyl
function
term
nonoblig
chain
termin
use
nucleotid
modif
sugar
part
eg
posit
hinder
bind
next
nucleotid
caus
termin
nextround
synthesi
complementari
strand
chain
termin
also
report
immucillinadenosin
analogu
activ
ebola
viru
although
antivir
nucleo
ide
inde
possess
unnatur
deoxi
ribos
part
lead
nonoblig
chain
termin
except
natur
ribos
exist
brivudin
favipiravir
latter
molecul
mechan
behind
inhibitori
effect
viral
rna
synthesi
remain
uncertain
central
dogma
chain
termin
ensur
viral
dnarna
synthesi
fulli
shut
lead
power
antivir
effect
recogn
cellular
polymeras
nucleotid
might
disrupt
cellular
dnarna
synthesi
chain
termin
event
would
exclud
mutagen
effect
upon
host
cell
valid
altern
could
design
nucleotid
mimet
coval
incorpor
viral
dna
rna
instead
act
strong
noncoval
blocker
polymeras
activ
site
one
way
introduc
triphosphatelik
moieti
mimic
interact
phosphat
relat
approach
design
mimet
transit
state
polymeras
enzym
drug
concept
yield
superior
enzym
inhibitor
field
hiv
proteas
influenza
neuraminidas
nribosyltransferas
enzym
given
virus
reli
fast
replic
genom
gener
million
billion
particl
per
day
nucleotid
show
tight
bind
viral
polymeras
could
produc
strong
antivir
effect
even
activ
site
block
nucleotid
would
recogn
cellular
polymeras
fair
assum
would
free
mutagen
new
gener
antivir
nucleo
ide
cours
select
high
barrier
drugresist
hiv
rt
one
common
resist
mechan
relat
higher
fidel
mutant
better
discrimin
natur
unnatur
dntp
link
mutant
rigid
activ
site
structur
suggest
unnatur
analogu
higher
structur
flexibl
still
adopt
mutat
site
henc
remain
activ
mutant
viru
downsid
ligand
flexibl
may
reduc
antivir
potenc
affect
bind
paramet
toward
protein
target
perhap
time
consid
less
explor
scaffold
search
new
nucleo
ide
antivir
regardless
mechan
one
import
issu
relat
discrimin
viral
cellular
polymeras
mention
lack
proofread
activ
mani
virus
ie
virtual
rna
virus
combin
relianc
fast
genom
copi
kinet
intrins
factor
contribut
select
addit
acut
viru
infect
requir
shortterm
treatment
weak
inhibitori
effect
cellular
polymeras
expect
harmless
anoth
topic
design
antivir
nucleo
ide
prodrug
moieti
modul
drug
lipophil
tissu
distribut
organ
tropism
brincidofovir
lipid
conjug
show
increas
oral
bioavail
cn
penetr
cidofovir
parent
main
advantag
phosphoramid
drug
sofosbuvir
therapi
hepat
c
activ
liverexpress
enzym
expand
prodrug
toolbox
creativ
need
perhap
exploit
enzym
pathway
upregul
instanc
phagocyt
granulocyt
attract
toward
virusinfect
tissu
lung
alveolar
cell
bloodbrain
barrier
perhap
immuno
patholog
viru
infect
may
boost
specif
enzym
reaction
infect
organ
avail
genomewid
proteom
metabolom
profil
provid
clue
enzym
could
consid
one
drawback
enzym
may
confin
primari
cell
complex
tissu
harder
isol
manipul
infect
virus
vitro
studi
conclud
antivir
nucleo
ide
aliv
kick
versatil
ubiquit
dnarna
build
block
relentless
sourc
imagin
medicin
chemist
biochemist
virologist
new
structur
analogu
protid
prodrug
need
design
consolid
lead
posit
nucleo
ide
analogu
field
antivir
therapi
hard
time
came
grant
ran
fund
sourc
dri
took
job
contractor
usamriid
work
nearli
three
year
return
usu
ever
sinc
work
current
research
professor
appoint
still
soft
money
posit
onset
career
usu
uncomfort
soft
money
sinc
money
well
go
dri
usamriid
much
greater
determin
make
soft
money
posit
work
usamriid
conduct
antivir
studi
orthopox
virus
abl
obtain
fund
poxviru
work
usu
gave
jumpstart
back
academia
moreov
still
interact
one
colleagu
usamriid
era
mike
bray
current
editorinchief
antivir
research
one
interest
thing
occur
year
left
usamriid
interview
us
postal
servic
work
fbi
investig
peopl
may
involv
anthrax
terror
attack
investig
usamriid
colleagu
steve
hatfil
main
terrorist
suspect
time
later
steve
exoner
case
career
taken
mani
turn
year
eb
flow
medic
need
time
signific
work
accomplish
career
earli
particip
preclin
develop
ganciclovir
five
compani
vy
right
compound
syntex
emerg
victori
excit
time
ganciclovir
hot
topic
mani
peopl
interest
anoth
signific
part
career
develop
new
anim
model
viral
infect
divers
includ
develop
differ
type
herpesviru
infect
immunocompromis
mice
new
orthopoxviru
model
new
model
arenavirus
bunyavirus
orthomyxovirus
latter
categori
excit
work
broad
array
differ
rna
virus
isar
news
vol
e
passion
year
perform
anim
studi
anim
experiment
rubber
meet
road
term
antivir
compound
potenti
becom
drug
read
mani
articl
scientif
literatur
vitro
activ
tout
evid
efficaci
anim
report
later
compound
fell
waysid
due
lack
vivo
efficaci
approach
taken
institut
antivir
research
publish
result
cell
cultur
anim
test
data
articl
anim
work
forev
play
key
role
drug
develop
continu
research
discoveri
new
anim
model
essenti
along
line
one
recent
project
group
develop
enteroviru
mous
model
report
icar
meet
colleagu
bart
tarbet
lead
research
project
sinc
relat
rhinovirus
mous
model
may
serv
surrog
antirhinoviru
compound
evalu
compound
also
inhibit
use
model
demonstr
guanidin
activ
inhibit
viru
replic
rupintrivir
rupintrivir
highli
potent
vitro
picornavirus
fail
treat
rhinoviru
infect
clinic
new
anim
model
infect
exist
earli
stage
rupintrivir
develop
compani
would
abl
find
ineffect
compound
long
invest
expens
clinic
trial
modeofact
studi
also
highli
interest
abl
lot
work
area
ganciclovir
project
much
current
satisfi
take
compound
noth
known
actual
figur
compound
work
icar
meet
year
often
hear
interest
mode
action
present
career
rub
shoulder
great
men
scienc
mentor
graduat
school
robert
sidwel
eight
year
later
work
utah
state
univers
retir
attend
mani
icar
meet
togeth
year
year
passion
trip
go
nice
restaur
even
insist
go
along
would
take
wood
swamp
look
reptil
new
orlean
icar
work
close
john
martin
current
ceo
gilead
scienc
chemist
syntex
key
player
team
develop
ganciclovir
mani
individu
collabor
project
member
isar
icar
meet
bring
divers
disciplin
togeth
chanc
interact
facetofac
colleagu
otherwis
visit
email
occasion
telephon
involv
mani
virus
research
interest
icar
import
meet
get
one
venu
also
enjoy
serv
variou
isar
committe
emerg
reemerg
virus
arlington
va
usa
octob
meet
organ
elsevi
confer
aim
ask
basic
hostcel
biolog
contribut
understand
emerg
reemerg
virus
help
surveil
well
vaccin
drug
develop
meet
bring
infectiousdiseas
specialist
togeth
research
interest
host
respons
virus
immunolog
cellbiolog
pharmacolog
viewpoint
confer
focu
rang
octob
isar
news
vol
e
human
pathogen
virus
constantli
emerg
reemerg
highlight
recent
ebola
outbreak
west
africa
ongo
zika
viru
outbreak
america
meet
held
arlington
va
usa
octob
hotel
conveni
locat
minut
washington
dc
citi
varieti
contrast
central
area
beauti
design
broad
avenu
line
magnific
build
monument
set
spaciou
green
park
inform
go
websit
http
august
confer
center
innov
therapeut
approach
virolog
meet
aim
perfect
platform
research
scientist
professor
student
exchang
discuss
idea
field
virolog
anticip
around
particip
around
globe
threeday
confer
includ
plenari
session
keynot
speech
poster
oral
present
inform
regard
confer
found
websit
http
wwwvirologycongresscom
th
annual
meet
escv
held
stresa
locat
lago
maggior
itali
septemb
scientif
program
compris
present
symposia
discuss
open
session
workshop
center
state
art
well
recent
discoveri
innov
clinic
virolog
main
topic
meet
includ
respiratori
virus
gastrointestin
virus
virusassoci
neurolog
syndrom
virusassoci
tumor
hepat
virus
hiv
retrovirus
virus
immunocompromis
patient
viral
infect
pregnanc
emerg
virus
immun
respons
viral
infect
advanc
diagnosi
monitor
advanc
prevent
treatment
famou
town
stresa
inhabit
sea
level
enjoy
splendid
locat
lake
maggior
gulf
borromeo
stresa
situat
northern
itali
ideal
posit
mountain
shore
borromean
gulf
beauti
countrysid
mild
climat
luxuri
villa
magnific
art
nouveau
hotel
made
town
stresa
perfect
combin
relax
cultur
stresa
easi
reach
three
borromean
island
steep
artist
histor
botan
appeal
detail
meet
found
meet
websit
